Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025

This cross-sectional study investigates the size of financial penalties levied by the US government against pharmaceutical companies accused of violating the Anti-Kickback Statute.

Corresponding Author: Reshma Ramachandran, MD, MPP, MHS, Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT 06510 (reshma.ramachandran@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.